Shelf life (days): 1460.0
Formulation: A solid
Formal Name: N-[(1S)-2-[[4-[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-pyridinyl]-2-thiazolyl]amino]-1-(methoxymethyl)-2-oxoethyl]-1-(methylsulfonyl)-1H-pyrrole-3-carboxamide
Purity: ≥98%
Formula Markup: C24H30N6O6S2
Formula Weight: 562.7
CAS Number: 2671128-05-3
Notes: FHD-286 is an inhibitor of Brahma homolog (BRM), also known as SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2), and Brahma-related gene 1 (BRG1), also known as SMARCA4.{72520} It induces differentiation of, and reduces viability in, MV4-11 and MOLM-13 acute myeloid leukemia (AML) cells, which express mixed-lineage leukemia 1 (MLL1) rearrangements, and OCI-AML-3 AML cells, which express mutant nucleophosmin 1 (NPM1), when used at a concentration of 30 nM. FHD-286 (100 nM) decreases BRG1-chromatin and BRM-chromatin associations in MOLM-13 cells. In vivo, FHD-286 (1.5 mg/kg) decreases tumor burden and increases survival in patient-derived xenograft (PDX) mouse models of AML when used alone or in combination with venetoclax (ABT-199; Item No. 16233), OTX015 (Item No. 15947), SNDX-5613 (Item No. 40758), or decitabine (Item No. 11166).
English
Deutsch
